EC
AKTX

EcoR1 Capital’s Akari Therapeutics AKTX Stock Holding History

EcoR1 Capital’s Portfolio AKTX Stock Details AKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-79
Closed -$856K – 32
2016
Q2 		$856K Sell
79
-36
-31% -$464K 0.34% 28
2016
Q1 		$1.29M Sell
115
-11
-9% -$114K 0.45% 31
2015
Q4 		$1.46M Hold
126
– – 0.46% 27
2015
Q3 		$2.42M Buy
+126
New +$1.49M 1.1% 16

Other funds holding AKTX

DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
VMI
VHCP Management II New York $379M AUM 421.62% 1-Year Est. Return
QF
QVT Financial New York $1.37B AUM 148.1% 1-Year Est. Return
FCMI
Foresite Capital Management III Larkspur, California $37.9M AUM 6.87% 1-Year Est. Return
VM
VHCP Management New York $93M AUM 10.04% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

EcoR1 Capital's AKTX Position: Q3 2016 in Review

EcoR1 Capital sold out of Akari Therapeutics (AKTX) in Q3 2016, closing a stake of 79 shares — an estimated $856K sold.

EcoR1 Capital first reported a position in AKTX in Q3 2015 and held it in 4 quarters. The position peaked at $2.42M in Q3 2015. 17 funds tracked by Wall St. Rank hold AKTX as of Q3 2016.

  • EcoR1 Capital reported no remaining Akari Therapeutics position as of Q3 2016 after selling out during the quarter.
  • EcoR1 Capital sold 79 Akari Therapeutics shares in Q3 2016, an estimated $856K.
  • EcoR1 Capital first reported a position in Akari Therapeutics in Q3 2015 and held it in 4 quarters.
  • EcoR1 Capital's Akari Therapeutics position peaked at $2.42M in Q3 2015.
  • 17 funds tracked by Wall St. Rank held Akari Therapeutics as of Q3 2016.

Based on EcoR1 Capital's 13F filing for Q3 2016, filed 14 Nov 2016.